USANA Health Sciences (NYSE: USNA) reported Q3 EPS of $0.59, $0.05 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $213 million versus the consensus estimate of $227.79 million.

GUIDANCE:

USANA Health Sciences sees FY2023 EPS of $2.80-$3.05, versus the consensus of $3.13. USANA Health Sciences sees FY2023 revenue of $900-920 million, versus the consensus of $930 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.